期刊
CLINICS IN CHEST MEDICINE
卷 39, 期 4, 页码 691-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2018.07.004
关键词
Biomarkers; Pneumonia diagnosis; Procalcitonin; Scoring systems; Prognosis
资金
- BioMerieux
- Roche Scientific
- ThermoFisher
Biomarkers are used in the diagnosis, severity determination, and prognosis for patients with community-acquired pneumonia (CAP). Selected biomarkers may indicate a bacterial infection and need for antibiotic therapy (C-reactive protein, procalcitonin, soluble triggering receptor expressed on myeloid cells). Biomarkers can differentiate CAP patients who require hospital admission and severe CAP requiring intensive care unit admission. Biomarker-guided antibiotic therapy may limit antibiotic exposure without compromising outcome and thus improve antibiotic stewardship. The authors discuss the role of biomarkers in diagnosing, determining severity, defining the prognosis, and limiting antibiotic exposure in CAP and ventilator-associated pneumonia patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据